Preclinical models of head and neck squamous cell carcinoma for a basic understanding of cancer biology and its translation into efficient therapies.
Organoids
Patient-derived primary cultures
Patient-derived xenografts
Personalized medicine
Preclinical models
Journal
Cancers of the head & neck
ISSN: 2059-7347
Titre abrégé: Cancers Head Neck
Pays: England
ID NLM: 101703807
Informations de publication
Date de publication:
2020
2020
Historique:
received:
25
03
2020
accepted:
15
07
2020
entrez:
28
7
2020
pubmed:
28
7
2020
medline:
28
7
2020
Statut:
epublish
Résumé
Comprehensive molecular characterization of head and neck squamous cell carcinoma (HNSCC) has led to the identification of distinct molecular subgroups with fundamental differences in biological properties and clinical behavior. Despite improvements in tumor classification and increased understanding about the signaling pathways involved in neoplastic transformation and disease progression, current standard-of-care treatment for HNSCC mostly remains to be based on a stage-dependent strategy whereby all patients at the same stage receive the same treatment. Preclinical models that closely resemble molecular HNSCC subgroups that can be exploited for dissecting the biological function of genetic variants and/or altered gene expression will be highly valuable for translating molecular findings into improved clinical care. In the present review, we merge and discuss existing and new information on established cell lines, primary two- and three-dimensional ex vivo tumor cultures from HNSCC patients, and animal models. We review their value in elucidating the basic biology of HNSCC, molecular mechanisms of treatment resistance and their potential for the development of novel molecularly stratified treatment.
Identifiants
pubmed: 32714605
doi: 10.1186/s41199-020-00056-4
pii: 56
pmc: PMC7376675
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
9Informations de copyright
© The Author(s) 2020.
Déclaration de conflit d'intérêts
Competing interestsThe authors declare that they have no competing interests.
Références
J Dent Res. 1954 Apr;33(2):253-62
pubmed: 13152263
Cancer Cell Int. 2019 Jan 14;19:16
pubmed: 30651721
Clin Cancer Res. 2018 Jan 1;24(1):158-168
pubmed: 29061642
Am J Pathol. 2012 Feb;180(2):599-607
pubmed: 22189618
Nat Rev Cancer. 2018 Jul;18(7):407-418
pubmed: 29692415
Cell Mol Gastroenterol Hepatol. 2018 Sep 14;7(1):73-91
pubmed: 30510992
Nature. 1988 Sep 15;335(6187):256-9
pubmed: 2970594
Nat Rev Cancer. 2005 Feb;5(2):127-35
pubmed: 15685196
Nature. 2019 May;569(7757):503-508
pubmed: 31068700
Oral Oncol. 2019 Nov;98:53-61
pubmed: 31541927
J Clin Invest. 2009 Nov;119(11):3408-19
pubmed: 19841536
J Oral Pathol. 1981 Jun;10(3):129-46
pubmed: 6798177
N Engl J Med. 2016 Nov 10;375(19):1856-1867
pubmed: 27718784
Nature. 2012 Mar 28;483(7391):603-7
pubmed: 22460905
Ann Oncol. 1992 Jul;3(7):513-26
pubmed: 1498071
Cancer Res. 2010 May 15;70(10):3925-34
pubmed: 20442295
Nature. 2009 May 14;459(7244):262-5
pubmed: 19329995
Oncogene. 2004 May 13;23(22):3972-9
pubmed: 15077191
Cancer Lett. 2013 Aug 28;337(1):115-24
pubmed: 23726841
Int J Cancer. 2017 Sep 15;141(6):1215-1221
pubmed: 28560858
Clin Cancer Res. 2018 Dec 15;24(24):6583-6593
pubmed: 30135147
Oncogene. 2018 Apr;37(14):1911-1925
pubmed: 29367767
Sci Rep. 2019 Aug 28;9(1):12480
pubmed: 31462653
Gastroenterology. 2011 Nov;141(5):1762-72
pubmed: 21889923
Oral Oncol. 2018 Dec;87:49-57
pubmed: 30527243
Cell. 2016 Jun 16;165(7):1586-1597
pubmed: 27315476
Mol Cancer Res. 2016 Mar;14(3):278-86
pubmed: 26685214
Int J Cancer. 2015 Jun 15;136(12):2940-8
pubmed: 25404014
Clin Cancer Res. 2013 Feb 15;19(4):855-64
pubmed: 23251001
Clin Cancer Res. 2011 Dec 1;17(23):7248-64
pubmed: 21868764
Lancet Oncol. 2019 Jun;20(6):e313-e326
pubmed: 31162105
Nat Med. 2015 Nov;21(11):1318-25
pubmed: 26479923
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Nat Commun. 2017 Sep 5;8(1):435
pubmed: 28874669
Cancer Discov. 2019 Jul;9(7):852-871
pubmed: 31053628
N Engl J Med. 2008 Sep 11;359(11):1116-27
pubmed: 18784101
J Clin Med. 2019 Nov 05;8(11):
pubmed: 31694307
Nat Commun. 2017 Sep 27;8(1):707
pubmed: 28955032
PLoS One. 2016 Aug 08;11(8):e0160615
pubmed: 27501241
Cell Tissue Res. 1991 Jun;264(3):563-76
pubmed: 1868523
J Dent Res. 1961 Jan-Feb;40:3-15
pubmed: 13772812
Neoplasia. 2013 May;15(5):461-71
pubmed: 23633918
Cell Rep. 2018 Oct 30;25(5):1332-1345.e5
pubmed: 30380422
Arch Otolaryngol Head Neck Surg. 2003 Jan;129(1):106-12
pubmed: 12525204
Lancet Oncol. 2016 Jul;17(7):956-965
pubmed: 27247226
Nat Med. 2006 Nov;12(11):1316-22
pubmed: 17057712
Blood. 2006 Jul 15;108(2):487-92
pubmed: 16410443
Cell Stem Cell. 2017 May 4;20(5):621-634.e6
pubmed: 28285905
Laryngoscope. 2017 Dec;127(12):2777-2783
pubmed: 28561270
Genome Med. 2014 Dec 12;6(12):116
pubmed: 25587359
Carcinogenesis. 2014 Mar;35(3):662-9
pubmed: 24148820
Cancer Res. 2016 Aug 15;76(16):4872-86
pubmed: 27221705
Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):301-13
pubmed: 14734483
Semin Oncol. 2014 Apr;41(2):217-34
pubmed: 24787294
Head Neck. 2010 Apr;32(4):417-26
pubmed: 19760794
Cancer Res. 2009 May 15;69(10):4159-66
pubmed: 19435901
Cell Rep. 2018 Oct 30;25(5):1318-1331.e4
pubmed: 30380421
Int J Cancer. 2015 Mar 15;136(6):1263-75
pubmed: 25082302
J Natl Cancer Inst. 2015 Jun 10;107(9):
pubmed: 26063791
Br J Cancer. 1981 Jun;43(6):772-85
pubmed: 7195729
Int J Cancer. 1992 Apr 22;51(1):99-107
pubmed: 1563848
Nat Commun. 2019 Dec 5;10(1):5546
pubmed: 31804466
Nat Rev Immunol. 2020 May;20(5):279-293
pubmed: 31853049
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Arch Otolaryngol. 1981 Nov;107(11):703-10
pubmed: 7295166
Nature. 2018 Aug;560(7718):325-330
pubmed: 30089904
J Transl Med. 2013 Aug 27;11:198
pubmed: 23981300
Oral Oncol. 2013 Sep;49(9):887-892
pubmed: 23910564
Mol Carcinog. 2019 May;58(5):666-673
pubmed: 30575147